ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 028,28
1,13%
Dow Jones
41 488,19
1,65%
DAX
22 986,82
2,01%
Brent Oil
70,285
0,00%
Bitcoin
83 685,32
-0,78%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. 4D Molecular Therapeutics Inc (FDMT)

  7. 4D Molecular Therapeutics Inc (FDMT) Actualités

FDMT

4D Molecular Therapeutics (FDMT)

4D Molecular Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:FDMT
DateHeureSourceTitreSymboleSociété
11/03/202501h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
10/03/202513h00GlobeNewswire Inc.4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMDNASDAQ:FDMT4D Molecular Therapeutics Inc
28/02/202523h07Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:FDMT4D Molecular Therapeutics Inc
28/02/202522h57Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FDMT4D Molecular Therapeutics Inc
28/02/202522h27Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:FDMT4D Molecular Therapeutics Inc
28/02/202522h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
28/02/202522h09Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:FDMT4D Molecular Therapeutics Inc
28/02/202522h05GlobeNewswire Inc.4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming MilestonesNASDAQ:FDMT4D Molecular Therapeutics Inc
19/02/202514h00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferencesNASDAQ:FDMT4D Molecular Therapeutics Inc
15/02/202500h09Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202520h30GlobeNewswire Inc.4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration ProgramNASDAQ:FDMT4D Molecular Therapeutics Inc
29/01/202514h00GlobeNewswire Inc.4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD PopulationNASDAQ:FDMT4D Molecular Therapeutics Inc
10/01/202514h00GlobeNewswire Inc.4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash RunwayNASDAQ:FDMT4D Molecular Therapeutics Inc
10/01/202514h00GlobeNewswire Inc.4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational PathNASDAQ:FDMT4D Molecular Therapeutics Inc
16/12/202414h00GlobeNewswire Inc.4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVSNASDAQ:FDMT4D Molecular Therapeutics Inc
06/12/202422h28Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
14/11/202414h00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIVNASDAQ:FDMT4D Molecular Therapeutics Inc
13/11/202422h27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FDMT4D Molecular Therapeutics Inc
13/11/202422h05GlobeNewswire Inc.4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming MilestonesNASDAQ:FDMT4D Molecular Therapeutics Inc
23/09/202414h00GlobeNewswire Inc.4DMT Announces Presentation at the 2024 North American Cystic Fibrosis ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
18/09/202422h05GlobeNewswire Inc.4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development DayNASDAQ:FDMT4D Molecular Therapeutics Inc
05/09/202414h00GlobeNewswire Inc.4DMT Announces Presentations at Upcoming Retina ConferencesNASDAQ:FDMT4D Molecular Therapeutics Inc
03/09/202414h00GlobeNewswire Inc.4DMT to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
27/08/202414h00GlobeNewswire Inc.4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024NASDAQ:FDMT4D Molecular Therapeutics Inc
12/08/202414h00GlobeNewswire Inc.4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
08/08/202422h05GlobeNewswire Inc.4DMT Reports Second Quarter 2024 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
05/08/202414h00GlobeNewswire Inc.4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory BoardNASDAQ:FDMT4D Molecular Therapeutics Inc
17/07/202411h00GlobeNewswire Inc.4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical ActivityNASDAQ:FDMT4D Molecular Therapeutics Inc
10/07/202423h17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
24/06/202414h00GlobeNewswire Inc.4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic AtrophyNASDAQ:FDMT4D Molecular Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FDMT

Dernières Valeurs Consultées

BIT
NSCITA1G0DQ7
European Financial Stabi...
BTRX
TRACUSDT
OriginTrail Trace
TG
A3K66Z
Toyota Motor Credit
COIN
PLEEETH
Plethori
BIT
P1HHT1
BNP Paribas Issuance BV
TG
MS8KKC
Morgan Stanley
COIN
STQGBP
Storiqa
TG
A28V1E
EnBW International Finan...
ASX
WBCHDD
Westpac Banking
TG
A2812K
Mondelez
AMEX
LIV
Emles at Home ETF
TG
A3LU38
Madrid Province
COIN
VSFUSD
VeriSafe
TG
A3LH6T
MercedesBenz
ASX
SGRCD
Star Entertainment
COIN
TENGBP
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces